Fusion Antibodies plc (FAB.L) Research

Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.

Market snapshot

Symbol
FAB.L
Price
$12.50
Day change
+4.17%
Market cap
$15.6M
P/E ratio
-9.65x
52-week range
6-21
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Abingdon Health Plc (ABDX.L)
  • Aptamer Group plc (APTA.L)
  • Cizzle Biotechnology Holdings Plc (CIZ.L)
  • Cambridge Cognition Holdings Plc (COG.L)
  • Futura Medical plc (FUM.L)
  • Genflow Biosciences plc (GENF.L)
  • Inspiration Healthcare Group plc (IHC.L)
  • IXICO plc (IXI.L)

Open Fusion Antibodies plc (FAB.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.